Literature DB >> 14986156

Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice.

C Quentin1, C Arpin, V Dubois, C André, I Lagrange, I Fischer, J-P Brochet, F Grobost, J Jullin, B Dutilh, G Larribet, P Noury.   

Abstract

Antibiotic resistance among members of the family Enterobacteriaceae was prospectively surveyed by eight French private laboratories over a 5-month period in 1999. A total of 2,599 consecutive and nonduplicate strains were collected, mainly (60.9%) from patients in the community. Most strains (82.9%) derived from urine. Escherichia coli was the predominant (73.9%) organism isolated. The overall rates of antibiotic resistance were as follows: amoxicillin, 53.4%; amoxicillin-clavulanic acid, 27.3%; ticarcillin, 44.2%; piperacillin-tazobactam, 3.2%; cephalothin, 29.2%; cefuroxime, 14.7%; cefoxitin, 11.5%; ceftazidime, 3.6%; cefotaxime, 2.8%; cefepime, 0.3%; imipenem, 0.1%; gentamicin (G), 3.8%; tobramycin (T), 5.0%; netilmicin (Nt), 3.7%; amikacin (A), 0.7%; nalidixic acid, 14.3%; ofloxacin, 10.4%; cotrimoxazole, 21.1%; nitrofurantoin, 12.7%; fosfomycin, 5.2%; tetracycline, 50.1%; and colistin, 12.5%. Beta-lactam resistance phenotypes essentially comprised penicillinase production (33.9%), overexpression of chromosomal cephalosporinase (4.6%), and synthesis of inhibitor-resistant TEM/OXA enzymes (1.5%) or extended-spectrum beta-lactamases (1.5%). Aminoglycoside resistance phenotypes consisted of GTNt (93 strains), TNtA (68 strains), GTNtA (14 strains), T (4 strains), GT (3 strains), G (1 strain), and reduced uptake/permeability (3 strains). Most of the nalidixic acid-resistant strains were resistant to ofloxacin (72.8%). Antibiotic resistance rates and phenotypes varied widely according to the bacterial group and the source of the strains. Significantly higher rates were observed in private healthcare centers than in the community, due to a higher proportion of both resistant species and resistant strains. However, multidrug-resistant isolates, including five extended-spectrum beta-lactamase-producing strains, were also recovered from the community.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986156     DOI: 10.1007/s10096-003-1081-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  37 in total

Review 1.  Has resistance spread to the community?

Authors:  P Heseltine
Journal:  Clin Microbiol Infect       Date:  2000-08       Impact factor: 8.067

2.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Antimicrobial resistance patterns in urinary isolates from nursing home residents. Fifteen years of data reviewed.

Authors:  M Vromen; A J van der Ven; A Knols; E E Stobberingh
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

4.  [Urinary tract infection in an urban population: etiology and antibiotic sensitivity as a function of patient history].

Authors:  D De Mouy; J D Cavallo; M Armengaud; J P Arzouni; J L Berges; J P Bouilloux; N Charbit; N Cirioni; R Fabre; E Garrabe; J Galinier; A Gayon; F Grobost; G Larribet; J P Lepargneur
Journal:  Presse Med       Date:  1999-10-09       Impact factor: 1.228

Review 5.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

6.  TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacae.

Authors:  Corinne Arpin; Roger Labia; Véronique Dubois; Patrick Noury; Muriel Souquet; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.

Authors:  G H Miller; F J Sabatelli; R S Hare; Y Glupczynski; P Mackey; D Shlaes; K Shimizu; K J Shaw
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

8.  Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland.

Authors:  K Hryniewicz; K Szczypa; A Sulikowska; K Jankowski; K Betlejewska; W Hryniewicz
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

9.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

Authors:  J Wiener; J P Quinn; P A Bradford; R V Goering; C Nathan; K Bush; R A Weinstein
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

10.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Authors:  L B Rice; E C Eckstein; J DeVente; D M Shlaes
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

View more
  6 in total

1.  Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.

Authors:  Corinne Arpin; Laure Coulange; Véronique Dubois; Catherine André; Isabelle Fischer; Sophie Fourmaux; Frédéric Grobost; Jacqueline Jullin; Brigitte Dutilh; Jean-Francois Couture; Patrick Noury; Isabelle Lagrange; Aline Ducastaing; Henri-Pierre Doermann; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

2.  The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis.

Authors:  S E Blair; N N Cokcetin; E J Harry; D A Carter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-10       Impact factor: 3.267

3.  Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.

Authors:  Corinne Arpin; Véronique Dubois; Jeanne Maugein; Jacqueline Jullin; Brigitte Dutilh; Jean-Philippe Brochet; Gilberte Larribet; Isabelle Fischer; Claudine Quentin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location.

Authors:  José Miguel Sahuquillo-Arce; María Selva; Hèctor Perpiñán; Miguel Gobernado; Carmen Armero; Antonio López-Quílez; Francisco González; Hermelinda Vanaclocha
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

5.  Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France.

Authors:  A Malmartel; C Ghasarossian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-06       Impact factor: 3.267

6.  Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.

Authors:  Agnès Meybeck; Jean-Damien Ricard; Guilène Barnaud; Mathieu Eveillard; Guillaume Chevrel; Roman Mounier; Didier Dreyfuss
Journal:  BMC Infect Dis       Date:  2008-05-17       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.